• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
    • {%itemName%} {%arrowSpan%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for Irish Healthcare Professionals only

      Duodopa®: Extensive world-wide experience1-3

      >61,000 years
      of patient experience1


      17 years
      established safety profile3,4

      Dosing flexibility 
      of up to 200ml/4000mg from two 100ml cassettes4

      Gold standard
      levodopa formulation4,5


      1,787 patients studied 
      across 11 individual post-marketing studies6-16

      >900 published scientific citations2

      1. Data on File. AbbVie, Inc., ABVRRTl72052.

      2. Data on File. AbbVie, Inc.

      3. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu301035 (Accessed November 2022).

      4. Duodopa® Summary of Product Characteristics, available on www.medicines.ie.

      5. Boyd JT, et al. Clin Park Relat Disord. 2020;2:25-34.

      6. Valldeoriola F, et al. Mov Disord. 2018; 33 (suppl.2).

      7. Fasano A, et al. Mov Disord. 2021; https://doi.org/10.1002/mds.28596.

      8. Palhagen SE, et al. Parkinsonism Relat Disord. 2016;29:17-23.

      9. Aldred J, et al. Neurodegener Dis Manag. 2020;10:309-23.

      10. Valldeoriola F, et al. Neurodegener Dis Manag. 2016;6:289-98.

      11. Antonini A, et al. Parkinsonism Relat Disord. 2017;45: 13-20.

      12. Lopiano L, et al. J Neural. 2019;266:2164-76. 

      13. Kruger R, et al. Adv Ther. 2017;34:1741-52.

      14. Aldred J, et al. Mov Disord. 2020;35 (suppl. 1 ).

      15. Tessitore A, et al. J Neural. 2018;265:1124-37.

      16. Antonini A, et al. J Neural Transm. 2020;127:881-91.

      17. Olanow CW, et al. Lancet Neurol. 2014;13:141-9.

      18. Slevin JT, et al. J Parkinsons Dis. 2015;5:165-74.

      19. Fernandez HH, et al. Mov Disord. 2015;30:500-9.

      20. Fernandez HH, et al. Mov Disord. 2018;33:928-36.

      21. Nyholm D, et al. AAPS J. 2013; 15:316-23.

      22. Standaert DG, et al. Mov Disord Clin Pract. 2017;4:829-37.

      23. Murata M, et al. Ther Adv Neurol Disord. 2018; 11: 1-11.

      24. Othman AA, et al. Clin Pharmacokinet. 2015;54:975-84.

      25. Freire-Alvarez E, et al. Mov Disord. 2021 ;36(11 ):2615-23.

      26. Antonini A, et al. Adv Ther. 2021 ;38:2854-90.

      Why Duodopa®?



      IE-DUOD-220036. Date of preparation: November 2022.

      Duodopa®: Robust clinical evidence

      Duodopa® is supported by a clinical development programme of 11 studies17-25

      LCIG=Levodopa/carbidopa intestinal gel; QoL=Quality of life 

      *S187.3.001 and S187.3.002 were combined in a single publication.

      S187.3.003 was an open-label extension study of S187.3.001 and S187.3.002. 

      S187.3.005 involved patients from S187.3.001, S187.3.002, S187.3.003 and S187.3.004. 

      §M12-923 was an extension of M12-921.

      Duodopa®: Published evidence

      Duodopa® is the only approved levodopa/carbidopa intestinal gel with >900 published scientific citations2

      PD=Parkinson's disease